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1012Objective: Effects of ventricular restraint on the left ventricle are well documented, but effects on the right ven-
tricle are not. We hypothesized that restraint affects the right and left ventricles differently.
Methods:We studied acute effects of restraint on left and right ventricular mechanics in healthy sheep (n ¼ 14)
with our previously described technique of adjustable and measurable restraint. Transmural pressure, myocardial
oxygen consumption indices, diastolic compliance, and end-systolic elastance were assessed at 4 restraint levels
for both ventricles. We then studied long-term effects of restraint for 4 months in an ovine model of ischemic
dilated cardiomyopathy (n ¼ 6). Heart failure was induced by coronary artery ligation, and polypropylene
mesh was wrapped around the heart to simulate clinical restraint therapy. All subjects were followed up with serial
cardiac magnetic resonance imaging to assess left and right ventricular volumes and function.
Results: Restraint decreased left ventricular transmural pressure (P< .03) and myocardial oxygen consumption
indices (P<.05) but not left ventricular diastolic compliance (P¼ .52). Restraint had no effect on right ventricular
transmural pressure (P¼ .82) or myocardial oxygen consumption indices (P¼ .72) but reduced right ventricular
diastolic compliance (P< .01). In long-term studies, restraint led to reverse left ventricular remodeling with de-
creased left ventricular end-diastolic volume (P< .006) but did not affect right ventricular end-diastolic volume
(P ¼ .82).
Conclusions: Ventricular restraint affects the left and right ventricles differently. Benefits of restraint for right
ventricular function are unclear. The left ventricle can tolerate more restraint than the right ventricle. With current
devices, the right ventricle may limit overall therapeutic efficacy. (J Thorac Cardiovasc Surg 2010;139:1012-8)Ventricular restraint is a nontransplant surgical treatment for
heart failure in which the entire epicardial surface is wrapped
with a prosthetic material.1,2 The intent is to provide circum-
ferential diastolic support to the failing heart and prevent
progressive ventricular remodeling. Although no clinically
approved restraint device is currently available for use, nu-
merous animal studies and clinical trials have demonstrated
that devices such as the Acorn CorCap Cardiac Support De-
vice (Acorn Cardiovascular, Inc, St Paul, Minn) can induce
reverse remodeling of the left ventricle (LV) and lead to im-
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The Journal of Thoracic and Cardiovascular Surricity index.3-14 The precise mechanics through which
restraint engenders these changes, however, remains un-
known. With our previously described technique in which
the amount of applied restraint can be measured and quanti-
fied (Figure 1), we demonstrated that ventricular restraint de-
creases LV transmural myocardial pressure (Ptm) and indices
of myocardial oxygen consumption (MvO2) in a large animal
model.15-16 These results imply that decreased LV wall
stress is one mechanism through which restraint promotes
reverse remodeling. We also showed that restraint level de-
termines the degree of improvement in Ptm and indices of
MvO2, implying that the amount of restraint applied is criti-
cal in determining therapeutic efficacy.
Most published studies analyzing the effects of ventricu-
lar restraint have focused on the LV, because LV dysfunc-
tion is the primary pathology for which restraint therapy is
indicated. Thus restraint has logically targeted improvement
in LV function. All current ventricular restraint devices,
however, involve the application of epicardial pressure
around the entire heart, including the right ventricle (RV).
Because the RV is restrained, alterations in right heart me-
chanics and physiology are possible. To date, however, there
have been no definitive studies evaluating the effect of ven-
tricular restraint on the RV.
In this study, we hypothesized that ventricular restraint
has different effects on RV function and mechanics than
on those of the LV. We tested this hypothesis by performinggery c April 2010
Abbreviations and Acronyms
AMVR ¼ adjustable and measurable
ventricular restraint
Cd ¼ diastolic compliance
CVP ¼ central venous pressure
EDP ¼ end-diastolic pressure
EDV ¼ end-diastolic volume
Ees ¼ end-systolic elastance
EF ¼ ejection fraction
LV ¼ left ventricle
MAP ¼ mean arterial pressure
MvO2 ¼ myocardial oxygen consumption
Pmax ¼ maximal pressure tested
Ptm ¼ transmural myocardial pressure
RV ¼ right ventricle
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Study Overview
This study was performed in 2 parts. (1) Acute, terminal studies evalu-
ated the effect of ventricular restraint level on RV and LV Ptm, indices of
MvO2, compliance, and hemodynamics. (2) Long-term, 4-month longitudi-
nal studies investigated the effects of simulated clinical restraint on RV and
LV remodeling in an ovine model of ischemic dilated cardiomyopathy.
A total of 20 (14 for acute studies, 6 for long-term studies) adult male
sheep (weight range 30–40 kg) were used in this study. All animals received
humane care in compliance with the Guide for Care and Use of Laboratory
Animals (www.nap.edu/catalog/5140.html). The protocol was approved by
the Institutional Animal Care and Use Committee at Harvard Medical
School.
Acute Studies: Effects of Restraint Level on
Ventricular Mechanics
Adjustable and measurable ventricular restraint. Be-
cause current clinical restraint devices such as the Acorn CorCap Cardiac
Support Device do not allow either the measurement or adjustment of
wrap tightness, restraint is applied at an arbitrary level of tightness.6,9,23
To address these limitations, we have previously developed and described
adjustable and measurable ventricular restraint (AMVR), in which a fluid-
filled epicardial balloon is placed around the entire ventricular surface.16
The balloon is surgically placed around the heart and secured to the atrio-
ventricular groove.
The AMVR balloon is hemiellipsoidal in shape and composed of medi-
cal grade polyurethane sheets (Polyzen, Inc, Apex, NC). Each balloon is
composed of two 1-mm thick layers. The outer layer of the balloon is flex-
ible but nonstretchable, whereas the inner layer is redundant. An access line
placed between the layers allows measurement of the pressure within the
balloon lumen, as well as the addition or withdrawal of fluid. Because the
outer layer of the balloon is nonstretchable, fluid introduced into the balloon
lumen has only one direction of filling space–inward, toward the heart. This
creates a tighter wrap. Conversely, withdrawal of fluid from the balloon lu-
men creates a looser wrap. The balloon access line is connected to a Statham
P10EZ pressure transducer (SpectraMed, Oxford, Calif). By measuring the
luminal pressure within the balloon when the heart is largest—end dias-The Journal of Thoracic and Cartole—wrap tightness (or restraint level) may be precisely quantified. To
change restraint level, fluid is added or removed from the balloon while bal-
loon luminal pressure is monitored in real time. At end diastole, the fluid
within the balloon lumen and access line is static. Cardiac magnetic reso-
nance imaging has confirmed this (unpublished data). Because the fluid is
static, the pressure measured by the access line should reflect the entire bal-
loon luminal pressure.
Pressure–volume analysis. Fourteen normal sheep were placed
under general anesthesia and underwent AMVR balloon placement by me-
dian sternotomy. A 16-gauge intravenous line was placed in the left external
jugular vein for access and measurement of central venous pressure (CVP).
An electromagnetic aortic flow probe (Carolina Medical Electronics, King,
NC) was placed to measure aortic flow. High-fidelity micromanometers
(Millar Instruments, Houston, Texas) were placed in the LV, RV, and aorta.
An 8F conductance catheter for volume measurement (Webster Laborato-
ries, Baldwin Park, Calif) was placed in the RV or LV.17-19 All electrocar-
diographic and hemodynamic signals were sampled at 200 Hz. We
arbitrarily defined the maximal pressure tested (Pmax) in our study as the
level at which mean arterial pressure (MAP) fell by 10 mm Hg, indicative
of tamponade physiology. In our animal model, Pmax was 8.0 mm Hg.
For each subject, all signals were recorded at 4 sequential restraint levels:
0 (baseline), 3.0 mm Hg (Pmax/3), 5.0 mm Hg (2Pmax/3), and 8.0 mm Hg
(Pmax). All data were collected for 20 beats and with the ventilator off to
avoid respiratory variations. The heart rate varied among animals (range
55–115 beats/min) but remained fairly consistent for any given subject at
all restraint levels tested. At each restraint level, an inferior vena caval oc-
clusion was performed to determine the RV and LV end-systolic elastance
(Ees) and diastolic compliance (Cd) values.
Data were analyzed on a microcomputer with the program MATLAB
(The Mathworks, Natick, Mass). End diastole was defined as the time point
in the cardiac cycle that corresponded to the R wave on the electrocardio-
gram, which closely represents closure of the mitral valve. Begin ejection
was defined as the point at which aortic flow first became nonzero, whereas
end systole was defined as the point at which aortic flow became zero after
the beginning of ejection. Hemodynamic signals were ensemble averaged
across 10 beats. Ptm across the heart wall was defined as the ventricular pres-
sure minus the epicardial pressure (as measured by the balloon). The trans-
mural tension–time index was calculated by integrating Ptm with respect to
time across the cardiac cycle. The end-systolic pressure–volume relation-
ship and the end-diastolic pressure–volume relationship were determined
from the caval occlusion data by the procedure of Kono and colleagues.20
The transmural pressure–volume area was calculated for each restraint
level.20-21Long-Term Studies: Effects of Restraint on
Ventricular Morphology and Function
Heart failure model. A postinfarction ovine model of heart failure,
previously described by Moainie and associates,22 was utilized. This model
includes many of the features of human ischemic dilated cardiomyopathy
and LV remodeling, such as increased LV end-diastolic volume (EDV)
and end-systolic volume, increased sphericity index, reduced LV EF, and
decreased systolic wall thickening. A left anterior thoracotomy was per-
formed through the 4th intercostal space in 6 sheep. The first 2 diagonal
branches of the left anterior descending coronary artery were identified
and ligated with 4-0 polypropylene sutures. The thoracotomy was closed
in layers, and the animal was allowed to recover. Cardiac magnetic reso-
nance imaging was performed 8 weeks after infarction to document heart
failure. By this time, heart failure developed in all animals, with LV EF
less than 40% and a 100% increase in LV EDV from baseline. There
was hypokinesis of the anterior to anterolateral wall, consistent with infarc-
tion of the area supplied by the ligated coronary arteries.
Simulated clinical ventricular restraint. To simulate clinical
restraint therapy, a polypropylene mesh (Ethicon, Inc, Somerville, NJ) wasdiovascular Surgery c Volume 139, Number 4 1013
FIGURE 1. Adjustable and measurable balloon ventricular restraint
(AMVR) device: a half-ellipsoidal fluid-filled balloon. Restraint level
may be quantified by measuring luminal pressure at end diastole. Restraint
level may be adjusted by changing the volume of fluid instilled in balloon.
The device is placed around both ventricles and secured to heart along the
atrioventricular groove.
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thesia, a median sternotomy was performed, and the mesh was placed
around the heart in accordance with guidelines used for placement of the
Acorn CorCap restraint device in clinical trials. The mesh was wrapped
around the heart and secured to the atrioventricular groove such that LV
EDV was decreased by 5% to 10% according to intraoperative epicardial
echocardiography.23,26 The incision was closed in layers, and the animal
was allowed to recover.FIGURE 2. Cardiac magnetic resonance imaging of ovine model of heart failure
cavity. B, Short-axis views of heart. C, Short-axis views with left ventricular (LV,
diastole.
1014 The Journal of Thoracic and Cardiovascular SurCardiac magnetic resonance imaging. Serial cardiacmagnetic
resonance imaging was performed in all animals at 8 weeks after coronary
ligation but before restraint wrap implantation to confirm development of
heart failure, and then bimonthly after wrap implantation (Figure 2). Imag-
ing was performed with a 3-T magnetic resonance scanner (Signa CV/i;
General Electric Healthcare, Milwaukee, Wis). All acquisitions were ob-
tained with an 8-element cardiac phased-array surface coil with the animal
in lateral decubitus position under general anesthesia and with proper ven-
tilation. Peripheral pulse gating and breath holding were used as much as
possible to minimize cardiac and respiratory motions, respectively. After
cardiac localization, cine imaging of cardiac function was performed with
cine steady-state free-precession fast-gradient echocardiography in 8 to 12
parallel short-axis slices (8-mm thickness, 0-mm skip) covering the entire
LV and 3 radial long-axis planes. Typical cine imaging parameters included
repetition time of 3.4 ms, echo time of 1.2 ms, flip angle of 45, number of
excitations of 2, in-plane spatial resolution of 1.53 1.5 mm, and views per
segment of 12, providing a temporal resolution of approximately 40 ms.24
Cine function analysis was performed off-line with validated software
(QMASS 7.1; Medis Medical Imaging Systems, Inc, Leiden, The Nether-
lands).25 The cardiac phase that demonstrated the largest LV cavity size
was defined as end diastole, and that with the smallest LV cavity size as
end systole. A single experienced observer manually traced the endocardial
contours of the RV and the LV to determine the ventricular chamber vol-
umes at end diastole and end systole. The papillary muscles were included
in the ventricular cavity volume (Figure 2, C). If the basal slice contained
both ventricular and atrial myocardium, the contours were drawn up to
the junction of the atrium and the ventricle and joined by a straight line
through the blood pool. For the RV basal slice in both end diastole and
end systole, if the pulmonary valve was visible, only the portion of the vol-
ume surrounded by trabeculated myocardium below the level of the pulmo-
nary valve was considered ventricle and included. For the inflow portion of
the RV, the blood volume was excluded from the RV volume if the. A, Four-chamber long-axis view showing position of heart within thoracic
red) and right ventricular (RV, yellow) endocardial borders delineated at end
gery c April 2010
TABLE 1. Effects of restraint level on hemodynamics, ventricular
mechanics, and myocardial energetics
Restraint level (mm Hg)
0 3 5 8
Mean arterial pressure (mm Hg) 53.2 54.2 44.7* 40.4*
Central venous pressure (mm Hg) 12.1 12.9 14.2* 16.7*
Left ventricle
Ptm (mm Hg) 31.8 28.1* 23.5* 18.7*
EDP (mm Hg) 7.3 7.8 7.9 8.5
Ees (mm Hg/mL) 0.46 0.43 0.44 0.53
Cd (mL/mm Hg) 2.94 2.43 2.09 3.12
TTI (mm Hg s) 16.8 14.5* 12.6* 10.0*
PVA (mm Hg mL) 2558 1983* 1461* 1299*
Right ventricle
Ptm (mm Hg) 10.8 10.8 10.9 10.5
EDP (mm Hg) 3.7 6.1* 7.9* 11.0*
Ees (mm Hg/mL) 0.7 0.97 0.85 1.06
Cd (mL/mm Hg) 10.76 6.9 4.98* 2.71*
TTI (mm Hg s) 6.5 6.7 6.9 7.2
PVA (mm Hg mL) 901 1486 1331 1164
Ptm, Transmural myocardial pressure; EDP, End-diastolic pressure; Ees, end-systolic
elastance; Cd, diastolic compliance; TTI, transmural tension–time index; PVA, trans-
mural pressure–volume area. *P< .05 for change from baseline.
Lee et al Evolving Technology/Basic Sciencesurrounding wall was thin and not trabeculated; rather, this was considered
to be part of the right atrium. RV EF and LV EFwere computed according to
the Simpson rule as the difference between EDV and end-systolic volume as
a percentage of EDV.
Anesthesia and Postoperative Care
For coronary ligation and ventricular wrap implantation, animals were
sedated with combined tiletamine hydrochloride and zolazepam hydrochlo-
ride (Telazol, 6 mg/kg intramuscularly) and endotracheally intubated. Anes-
thesia was maintained with 1% to 2% isoflurane. Animals received
magnesium (2 gm intravenously), amiodarone (1.5 mg/kg intravenously),
and lidocaine (3 mg/kg intravenously) before infarction and received an in-
fusion of amiodarone (0.01 mg/[kg min]) and lidocaine (2 mg/min) for 60
minutes afterward. Animals received buprenorphine (5 mg/kg intramuscu-
larly every 12 hours for 2 days) for pain control and cefazolin (4 mg/kg in-
tramuscularly every 12 hours for 2 days) for antibiotic prophylaxis.FIGURE 3. Acute effects of restraint on ventricular transmural and filling pressu
Left ventricular (LV) transmural pressure decreases with increasing restraint, whe
indicates P<.05 for change from baseline. B, Changes in end-diastolic pressure (
ventricular end-diastolic pressure shows minimal changes with increasing restra
with increases in restraint level. Central venous pressure increases at higher rest
The Journal of Thoracic and CarStatistical Analysis
All data are expressed as meanþ SD. A doubly multivariate general
linear mixed model with repeated measures design was used in both the
acute and long-term studies.27 In the acute study, changes in dependent
variables were assessed according to restraint level. In the long-term
study, changes in dependent variables were assessed with time. Post hoc
pairwise comparisons between different restraint levels or different time
points were performed with the Bonferroni post hoc test. Statistics were
performed with the SPSS statistical software package (version 12.0;
SPSS Inc, Chicago, Ill).RESULTS
Acute Studies
MAP, CVP, Ptm, end-diastolic pressure (EDP), Cd, Ees,
and indices of myocardial energetics for each restraint level
for both ventricles are summarized in Table 1. Ventricular
restraint did not have any significant effect on RV Ptm
(P ¼ .92) or indices of RV MvO2 (P ¼ .90). This is in con-
trast to the LV, where Ptm (P ¼ .03) and indices of MvO2
(P ¼ .002) decreased significantly with increasing amounts
of restraint (Figure 3, A). RV EDP rose (P¼ .02) as restraint
level was increased. Interestingly, there was a nearly linear
relationship between the increase in restraint level and the
rise in RV EDP (Figure 3, B). Restraint had no effect on
RV contractility Ees (P ¼ .43) but did cause a decrease in
RV Cd (P ¼ .01) and shifted the end-diastolic pressure–vol-
ume relationship to the left. This reduction in RV Cd was al-
most directly proportional to the increase in restraint level. In
contrast, restraint had no effect on LV Cd (P ¼ .52) or LV
Ees (P ¼ .72). At restraint levels of 5.0 mm Hg and higher,
MAP fell (P ¼ .04) and CVP rose (P ¼ .027). MAP de-
creased by more than 10 mm Hg at a restraint level of 8.0
mm Hg, consistent with tamponade physiology.Long-Term Studies
There was no significant change in RV size or function
with simulated clinical ventricular restraint (Figure 4). RVres. A, Ventricular transmural pressure (Ptm) as a function of restraint level.
reas right ventricular (RV) transmural pressure remains unchanged. Asterisk
EDP) and central venous pressure (CVP) as a function of restraint level. Left
int. Right ventricular end-diastolic pressure rises in a nearly linear manner
raint levels, consistent with tamponade.
diovascular Surgery c Volume 139, Number 4 1015
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FIGURE 4. Long-term effect of simulated clinical ventricular restraint on end-diastolic volume (EDV) and ejection fraction (EF). A, Left ventricular (LV)
end-diastolic volume decreases with time, whereas right ventricular (RV) end-diastolic volume remains unchanged. B, There is a trend toward improvement in
left ventricular ejection fraction, although this change is not statistically significant. Right ventricular ejection fraction is unaffected. Time at 0 weeks repre-
sents time of restraint wrap implantation. Asterisk indicates P< .05 for change from baseline.
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E
T
/B
SEDV values were 64.8 4.0 mL at baseline (just before im-
plantation of the restraint wrap) and 66.6  5.9 mL after 4
months of treatment (P ¼ .8). RV EF values were 60.0%
 5.9% at the start of therapy and 60.2%  8.1% after 4
months (P ¼ .7). In the LV, the simulated clinical restraint
wrap resulted in reverse remodeling during the study period
(Figure 4). There was a significant reduction in LV EDV,
from 106.1  10.0 mL at baseline to 99.3  8.2 mL after
4 months of therapy (P ¼ .006). There was a trend toward
improvement in LV EF, from 31.4%  9.1% at baseline
to 41.4%  5.6% after 4 months; however, this change
was not statistically significant (P ¼ .3).
DISCUSSION
The beneficial effects of ventricular restraint on LV mor-
phology and function have been well documented.10-13 Sev-
eral studies have demonstrated that restraint therapy can
prevent and even reverse pathologic LV remodeling as
well as improve global clinical functional status.3-9 We pre-
viously described a mechanistic explanation for these find-
ings: restraint decreases LV wall stress, as evidenced by
decreases in Ptm and indices of MvO2.
15-16 To date, however,
there have been no published investigations regarding the ef-
fects of restraint on RV mechanics and function.
Restraint therapy by definition can affect the epicardium
by either normal stresses (perpendicular forces) or shear
stresses (tangential forces). With the AMVR device, the
fluid within the balloon is effectively the sole means of
achieving restraint. Because a static fluid cannot apply shear
stresses, the AMVR balloon affects the epicardium by nor-
mal forces only. This is measurable as the pressure within
the balloon lumen and allows the quantification of both re-
straint level and its effects on ventricular mechanics.
To investigate the effect of restraint on each ventricle, we
first performed acute hemodynamic studies in which sys-
temic (CVP, MAP) and separate ventricular (EDP, Ptm,
Ees, Cd) parameters were measured and calculated as a func-1016 The Journal of Thoracic and Cardiovascular Surtion of restraint level in 14 normal sheep hearts. In these
acute studies, we found that as restraint level was increased
to progressively higher levels, LV Ptm continued to decrease
while effective LV Cd and LV Ees remained unaffected, cor-
roborating the results of our previous study.16 When re-
straint level was increased, the LV received the beneficial
effect of incremental decreases in LV transmural myocardial
pressure while LV diastolic stiffness and systolic contractil-
ity remained unchanged.
In contrast to the LV, our data show that any increase in
restraint level resulted in a nearly linear rise in RV filling
pressure, as measured by RV EDP (Figure 3, B). As a result,
RV Ptm did not change at all, regardless of the restraint level.
Furthermore, as restraint level was increased, overall effec-
tive RV Cd (the Cd of the restraint device plus that of the
RV) decreased. In other words, with the restraint device ap-
plied, the RV plus the restraint device apparatus became in-
creasingly stiffer in diastole as the restraint level was
increased. At higher restraint levels (where LV Cd was un-
changed), effective RV Cd was so diminished as to ulti-
mately impair ventricular filling. At restraint levels of 5
mmHg or greater, overall global tamponade physiology pre-
vailed. Even at these levels, however, the LV continued to
receive therapeutic benefit, as evidenced by decrease in
Ptm without any adverse change in effective LV Cd. We con-
clude that ventricular restraint affects the RV very differ-
ently than the LV.
Why should the mechanics of the RV plus restraint device
be different from those of the LV plus restraint device? We
postulate that the explanation is related to the thickness of
the ventricular wall and the native Cd of each ventricle.
The relatively thick wall of the LV is less compliant than
that of the thin-walled RV. Indeed, the normal RV is sub-
stantially more compliant than the LV in diastole (Table
1). We hypothesize that the restraint device acts as another
compliance chamber in series with the compliance of the na-
tive ventricle. The sum total of 2 compliance chambers ingery c April 2010
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values. Thus the addition of another compliance chamber
(the restraint device) in series with each ventricle would
cause the restraint device to have a substantially greater ef-
fect on overall RV mechanics relative to the LV, because
RV Cd is greater than that of the LV. The restraint device re-
duces effective RV Cd by a greater degree than its reduction
in effective LV Cd. We hypothesize that this is the cause of
the effects we measured.
In our acute study, at restraint levels of 5 mm Hg and
higher there was a significant rise in CVP and reduction in
MAP, consistent with overall global tamponade physiology.
What caused this tamponade? Was it due to adverse effects
of restraint on the LV or the RV? With increasing restraint
level, the RV became effectively stiffer with increased filling
pressures, whereas no changes in LV stiffness or filling pres-
sures were seen. We conclude that RV mechanics were re-
sponsible for the adverse hemodynamic changes causing
cardiac tamponade seen at higher restraint levels. Indeed,
in the acute studies, we saw no benefit to the RV from re-
straint therapy at any restraint level.
We sought to correlate findings from the acute studies
with those from the longitudinal, long-term study. Our aim
was to simulate ventricular restraint therapy as used in clin-
ical trials by applying a mesh wrap in a large-animal model
of ischemic dilated cardiomyopathy. The long-term study
confirmed that restraint induces reverse remodeling in the
LV, as other studies have shown. There was a significant de-
crease in LV EDV of 6.4% with our simulated clinical re-
straint therapy, consistent with results seen in clinical trials
of the Acorn CorCap device.3,4 The RV, in contrast, did
not demonstrate any significant changes in EDV or EF, ei-
ther before or after heart failure creation, or after the initia-
tion of restraint therapy. Both parameters remained
unchanged throughout the entire study duration. As pre-
dicted by our acute study results, we conclude that long-
term restraint in the setting of LV failure does not have
any substantial effect on the RV.
As with clinical devices, we were unable to measure or
quantify the amount of restraint applied with our mesh
wrap. On the basis of the combined results of the acute
and long-term studies, however, we surmise that the restraint
level applied in the long-term study was approximately 3.0
mm Hg or less. Our assumption is based on the acute study
data, in which a restraint level of 3.0 mm Hg yielded bene-
ficial changes in LV mechanics without any significant ad-
verse effect on the RV. Although the simplest way to
determine the amount of restraint applied would have been
to use the AMVR balloon in our long-term study, we did
not do so because our goal in the long-term study was to rep-
licate as accurately as possible the clinical use of restraint
wraps. Future research may overcome this limitation by us-
ing the AMVR balloon to apply restraint in long-term stud-
ies. We conclude that restraint therapy, in the scenario of LVThe Journal of Thoracic and Carfailure, can be applied to the entire epicardial surface at low
levels to successfully induce LV reverse remodeling without
impeding RV function.
One important limitation of this study is that this was not
an investigation of RV heart failure. We did not create RV
ischemia or dysfunction; RV volume and function remained
unchanged before and after diagonal branch coronary artery
ligation in our LV heart failure sheep model. In the long-
term study, restraint was thus applied to a dysfunctional
LV and a normal RV. Our long-term study subjects with nor-
mal RVs may not have shown any change in RV size or
function simply because their RVs were normal. Our conclu-
sions therefore may not necessarily be applicable in cases of
dilated cardiomyopathy involving primary RV failure.
Clinically, LV failure may or may not be accompanied by
RV failure or dilatation. Would restraint therapy be benefi-
cial for a patient with a dilated, dysfunctional RV? Theoret-
ically, restraint should unload the failing RV and promote
recovery of ventricular function just as in the left side of
the heart. Our acute study results, however, imply that re-
straint may not provide substantial benefit in RV failure.
The acute study was performed in healthy animals. In these
subjects with normal LVs, restraint caused decreased LV
Ptm, a key parameter identifying beneficial effects on the
ventricle. We previously demonstrated in similar short-
term studies that restraint leads to reductions of LV Ptm in
a dilated, failing LV as well.16 Unlike in the LV, however,
short-term studies of the normal RV did not demonstrate
any change in RV Ptm with restraint. This suggests that re-
straint may not cause a decrease in RV Ptm even in a dysfunc-
tional RV. Further investigation of restraint in the setting of
RV failure will be necessary to delineate more fully the role
of restraint in RV dysfunction.
In summary, we demonstrated that ventricular restraint af-
fects the RV and LV differently. Low levels of restraint can
be safely applied in LV dilated cardiomyopathy without im-
peding RV function. The benefit received by the RV in re-
straint therapy for LV heart failure is, however, unclear. At
higher restraint levels, the RV clearly limits overall therapy
because of adverse hemodynamic changes related to im-
paired RV filling. Our data suggest that each ventricle has
a different threshold for the amount of restraint that can be
applied before impaired filling develops and that individual
restraint levels, applied separately to each ventricle, might
optimize therapeutic efficacy.With current devices, in which
a single restraint level is applied simultaneously to both ven-
tricles, therapeutic efficacy may be limited because the re-
straint level that promotes optimal reverse LV remodeling
may higher than can be tolerated safely by the RV. Ventri-
cle-specific restraint, in which restraint levels are tailored
to each ventricle, may be required to optimize therapeutic ef-
ficacy. In the scenario of strict LV dysfunction, a partial re-
straint device, with restraint applied only to the LV
epicardium, would allow the application of very high levelsdiovascular Surgery c Volume 139, Number 4 1017
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danger of RV tamponade. Thus future efforts at restraint may
involve the simultaneous application of different restraint
levels to the LV and RV, with each level optimized for
each ventricle, as opposed to a single concomitant level cur-
rently applied to both ventricles.
We thank Drs Vakhtang Tchantchaleishvili and Dahai Wang for
assistance with data acquisition and Ethicon, Inc, Somerville, NJ,
for providing the polypropylene mesh used in this study.
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